Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 known ✓ | P22001 | 1/20 | 0.61 |
| ▸ | HTR1B known ✓ | P28222 | 2/20 | 0.48 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.48 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.48 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.48 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.48 |
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521039 | 0.98 | KCNA3 (0.64) | KCNA3TAAR1ALDH1A1RECQLLTA4H | |
| SCHEMBL10961516 | 0.89 | LTA4H (0.68) | KCNA3TAAR1ALDH1A1RECQLLTA4H | |
| SCHEMBL1715718 | 0.86 | KCNA3 (0.68) | KCNA3TAAR1ALDH1A1RECQLLTA4H | |
| SCHEMBL27962 | 0.84 | KCNA3 (0.82) | KCNA3TAAR1ALDH1A1RECQLLTA4H | |
| Hydrochloric Acid SCHEMBL8820504 | 0.82 | KCNA3 (0.56) | KCNA3TAAR1ALDH1A1RECQLLTA4H | |
| Ethylene SCHEMBL29058163 | 0.79 | KCNA3 (0.74) | KCNA3TAAR1ALDH1A1RECQLLTA4H | |
| SCHEMBL28011668 | 0.79 | TAAR1 (0.64) | KCNA3TAAR1ALDH1A1RECQLLTA4H | |
| Hydrochloric Acid SCHEMBL335050 | 0.78 | TAAR1 (0.95) | KCNA3TAAR1ALDH1A1RECQLLTA4H | |
| SCHEMBL2481801 | 0.77 | KCNA3 (0.70) | KCNA3TAAR1ALDH1A1RECQLLTA4H | |
| SCHEMBL11087417 | 0.77 | KCNA3 (0.70) | KCNA3TAAR1ALDH1A1RECQLLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023076586-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-11267826-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3630783-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20200102331-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-02 | — | — | US | disclosed |
| WO-2018218154-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2018-11-29 | — | — | WO | disclosed |
| EP-1789042-B1 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2012-05-02 | — | — | EP | disclosed |
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | disclosed |
| US-20100226875-A1 | CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM DYNAMIC MIXTURES | FIRMENICH SA (CH) | 2010-09-09 | — | — | US | disclosed |
| US-7579359-B2 | 1-alkoxy 1H-imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1789042-A4 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-2010293-A2 | CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM DYNAMIC MIXTURES | Firmenich S.A. (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-20090005376-A1 | imidazonaphthyridines, imidazopyridines, imidazoquinolines, and imidazote-trahydroquinolines; immunomodulators for inducing cytokine biosynthesis; for treatment of viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-01 | — | — | US | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| WO-2007085991-A2 | CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM DYNAMIC MIXTURES | FIRMENICH SA (CH) | 2007-08-02 | — | — | WO | disclosed |
| EP-1789042-A2 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-30 | — | — | EP | disclosed |
| CN-1906155-A | Novel hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA AS (DK) | 2007-01-31 | — | — | CN | disclosed |
| WO-2006028962-A2 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267826-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | KCNA3 4654/4885HTR1B 3286/4885HDAC3 4203/4885 |
| US-20100226875-A1 | CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM DYNAMIC MIXTURES | HPD, TRHDE, BPHL | KCNA3 577/4885HTR1B 391/4885HDAC3 925/4885 |
| US-20200102331-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | KCNA3 4654/4885HTR1B 3286/4885HDAC3 4203/4885 |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | F9, F12, HDAC9 | KCNA3 4232/4885HTR1B 1400/4885HDAC3 68/4885 |
| US-20090005376-A1 | imidazonaphthyridines, imidazopyridines, imidazoquinolines, and imidazote-trahydroquinolines; immunomodulators for inducing cytokine biosynthesis; for treatment of viral and neoplastic diseases | IL2, IL4, IRF3 | KCNA3 3561/4885HTR1B 3480/4885HDAC3 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.